Loading…
Viatris Inc. is projected to rise to $19.25 by 2027, a +18% move from its current price of $16.27. VTRS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $16.04 | $16.28 | $16.52 | +0.07% |
| Jul 13 | $15.95 | $16.29 | $16.64 | +0.13% |
| Jul 14 | $15.89 | $16.30 | $16.72 | +0.20% |
| Jul 15 | $15.84 | $16.31 | $16.80 | +0.27% |
| Jul 16 | $15.79 | $16.32 | $16.87 | +0.33% |
| Jul 17 | $15.75 | $16.33 | $16.94 | +0.40% |
| Jul 18 | $15.72 | $16.35 | $17.00 | +0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.72 | $16.35 | $17.00 | +0.46% |
| Week 2 | $15.54 | $16.42 | $17.35 | +0.93% |
| Week 3 | $15.42 | $16.50 | $17.65 | +1.40% |
| Week 4 | $15.33 | $16.57 | $17.92 | +1.87% |
| Week 5 | $15.26 | $16.65 | $18.17 | +2.34% |
| Week 6 | $15.20 | $16.73 | $18.41 | +2.82% |
| Week 7 | $15.16 | $16.81 | $18.64 | +3.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Viatris Inc. operates as a healthcare company with a broad geographic footprint across North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It runs in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
The company provides prescription brand drugs, generic drugs, complex generic drugs, and biosimilars, and covers therapeutic areas including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients manage their health.
The company distributes its medicines through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. Viatris was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. It has collaboration agreements with Mapi Pharma Ltd.
to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin.
Viatris Inc. is a healthcare company with a global footprint and a diversified portfolio spanning prescription brands, generics, complex generics and biosimilars. It operates across multiple regions and serves extensive therapeutic areas, supported by a distribution network that covers wholesalers, retailers, institutional pharmacies, and e-commerce channels.
The company is headquartered in Canonsburg, Pennsylvania, and has established collaborations with industry partners to advance specific products.
In the market, Viatris carries a current price of $16.70 and a market cap of $19.45B, with a rank of 592. The long-range forecast points to a multi-year upside, with average prices rising across the horizon and potential for substantial appreciation by 2050. The near-term range and technical backdrop imply a variable but constructive price path ahead.
A major floor 20.3% below — a decisive break under it would weaken the trend.
The nearest floor, 5.5% below — buyers have tended to step in here.
The nearest ceiling, 4.2% above — a clean break opens room to run.
A major ceiling 9.3% above — clearing it would confirm fresh momentum.
Key VTRS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VTRS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.61 | Sell | $16.45 | Sell |
| MA 10 | $16.43 | Sell | $16.39 | Sell |
| MA 20 | $16.19 | Buy | $16.27 | Buy |
| MA 50 | $16.18 | Buy | $15.91 | Buy |
| MA 100 | $15.23 | Buy | $15.17 | Buy |
| MA 200 | $13.39 | Buy | $13.89 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.19 | Neutral |
| Stoch RSI (14) | 44.81 | Neutral |
| CCI (20) | 16.62 | Neutral |
| Williams %R (14) | -43.67 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 3.30 | Buy |
| Bollinger %B (20,2) | 0.55 | Neutral |
| Stochastic %K (14) | 56.33 | Neutral |
| TRIX (15) | 0.09 | Buy |
| Awesome (5,34) | 0.47 | Buy |
| Ultimate (7,14,28) | 60.35 | Neutral |
| Momentum (10) | 0.20 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 16.57 | Sell |
| ADX (14) | 11.90 | Neutral |
| ATR (14) | 0.24 | Info |
The 30-day technical picture is bullish, with RSI14 at 60. The stock trades above key moving averages, with a SMA50 of $15.99 and a SMA200 of $13.22, suggesting a constructive trend. Support sits at $15.37 and resistance at $16.70, framing a near-term dynamic within a $15.04 to $18.54 30-day range.
Overall near-term momentum aligns with a bullish tilt, supported by price action within the established support and resistance framework and a willingness to test higher levels in the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.37 | $16.27 | $22.48 | 0% | Neutral | |
| $15.77 | $19.25 | $24.58 | +18% | Neutral | |
| $16.82 | $20.93 | $27.44 | +29% | Bullish | |
| $19.14 | $24.17 | $32.37 | +49% | Bullish | |
| $21.01 | $26.90 | $36.67 | +65% | Bullish | |
| $25.54 | $33.09 | $45.82 | +103% | Bullish | |
| $28.44 | $37.27 | $52.34 | +129% | Bullish | |
| $29.47 | $39.03 | $55.53 | +140% | Bullish | |
| $32.37 | $43.29 | $62.32 | +166% | Bullish | |
| $33.25 | $44.89 | $65.35 | +176% | Bullish | |
| $50.36 | $70.91 | $108.17 | +336% | Bullish | |
| $95.07 | $143.59 | $234.78 | +783% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $12.37 | $16.27 | $19.37 | +0.00% |
| August 2026 | $14.49 | $16.96 | $20.29 | +4.25% |
| September 2026 | $14.69 | $17.28 | $20.83 | +1.89% |
| October 2026 | $14.66 | $17.31 | $21.00 | +0.16% |
| November 2026 | $14.99 | $17.76 | $21.67 | +2.61% |
| December 2026 | $15.42 | $18.33 | $22.48 | +3.20% |
Click any year to see its month-by-month VTRS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect VTRS to range from $12.37 to $22.48 through 2026. The $16.27 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The VTRS price prediction for 2027 points to an average of $19.25 (low $15.77, high $24.58) — a potential gain of +18% on today's $16.27. A consolidation phase looks the most probable path here.
In 2028, VTRS is projected to trade between $16.82 and $27.44, averaging $20.93 — a potential gain of +29% from today's $16.27. That is up +9% on the projected 2027 average. Momentum favours further upside here.
Viatris Inc.'s 2029 outlook centres on $24.17, within a $19.14 to $32.37 range. That is up +15% on the projected 2028 average. That marks a +49% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, VTRS could reach as high as $36.67, with a base case around $26.90 and support toward $21.01 — roughly +65% from $16.27. Momentum favours further upside here.
Expect VTRS to range from $25.54 to $45.82 through 2031. The $33.09 average target implies a +103% move from current prices. That is up +23% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The VTRS price prediction for 2032 points to an average of $37.27 (low $28.44, high $52.34) — a potential gain of +129% on today's $16.27. Momentum favours further upside here.
In 2033, VTRS is projected to trade between $29.47 and $55.53, averaging $39.03 — a potential gain of +140% from today's $16.27. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Viatris Inc.'s 2034 outlook centres on $43.29, within a $32.37 to $62.32 range. That is up +11% on the projected 2033 average. That marks a +166% change versus current levels. Momentum favours further upside here.
By 2035, VTRS could reach as high as $65.35, with a base case around $44.89 and support toward $33.25 — roughly +176% from $16.27. Buyers look set to stay in control over this stretch.
Expect VTRS to range from $50.36 to $108.17 through 2040. The $70.91 average target implies a +336% move from current prices. That is up +58% on the projected 2035 average. Momentum favours further upside here.
The VTRS price prediction for 2050 points to an average of $143.59 (low $95.07, high $234.78) — a potential gain of +783% on today's $16.27. Buyers look set to stay in control over this stretch.
Investing $1,000 in VTRS today (≈ 61.462815 VTRS) could be worth
$8,825.2
+$7,825.2 (+783%) by 2050 · US Dollar
Based on the average projected VTRS price of $143.59 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VTRSwould be worth at today's price.
$1,000 invested in VTRS on Jul 10, 2025 (≈ 108.108108 VTRS) would be worth
$1,758.92
+$758.92 (+75.9%) today · 1.76× · US Dollar
Based on a VTRS entry price of $9.25 vs. today's $16.27.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.7 | $974.25 | -2.6% |
| 1 month ago | $15.77 | $1,031.71 | +3.2% |
| 3 months ago | $13.47 | $1,207.87 | +20.8% |
| 6 months ago | $12.68 | $1,283.12 | +28.3% |
| 1 year ago | $9.25 | $1,758.92 | +75.9% |
| All time (5.0y) ago | $14.18 | $1,147.39 | +14.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VTRS forecast.
Our base-case forecast reaches $33.00 around 2031.
Implied market cap at $33.00: $38.43B
The long-range forecast shows a steady uplift in average prices across years, with notable milestones: 2026 min $12.37, avg $16.70, max $23.18; 2027 avg $19.77, ROI 18.4; 2028 avg $21.75, ROI 30.3; 2029 avg $25.16, ROI 50.6; 2030 avg $27.94, ROI 67.3. Beyond, 2031 avg $34.64, ROI 107.4; 2032 avg $38.89, ROI 132.9; 2033 avg $40.62, ROI 143.2; 2034 avg $45.52, ROI 172.6; 2035 avg $46.90, ROI 180.8.
The forecast continues to show substantial upside, with 2040 avg $75.06, ROI 349.5, and 2050 avg $151.64, ROI 808, all while sentiment remains BULLISH in those later years. These figures illustrate a path to significantly higher levels over the long term, though they are estimates and not guarantees and are subject to market and company-specific risks.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $27.94, a min of $21.82 and a max of $38.10, with an estimated ROI of 67.3%.
The forecast shows bullish sentiment from 2027 onward, with rising averages and positive ROIs: 2027 avg $19.77 (ROI 18.4%), 2028 avg $21.75 (ROI 30.3%), 2029 avg $25.16 (ROI 50.6%), 2030 avg $27.94 (ROI 67.3%), 2040 avg $75.06 (ROI 349.5%), and 2050 avg $151.64 (ROI 808%). These are estimates, not guarantees.
Yes. The max forecasts reach $57.80 in 2033, $114.52 in 2040, and $247.97 in 2050.
Current price is $16.70 and market cap is $19.45B.
The 30-day range is $15.04 to $18.54.
Viatris Inc. Community Discussion
0Share your Viatris Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.